NCT05378997View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

March 16, 2024

Study Completion Date

March 16, 2024

Conditions
BlisterWound of SkinEpidermolysis BullosaVaricose Ulcer of Lower Limb
Interventions
DRUG

TCP-25 gel 0.86 mg/ml or placebo gel

TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

DRUG

TCP-25 gel 2.9 mg/ml or placebo gel

TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

DRUG

TCP-25 gel 8.6 mg/ml or placebo gel

TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

Trial Locations (1)

SE-221 85

Skåne University Hospital in Lund, Clinical Trial Unit, Lund

All Listed Sponsors
collaborator

Region Skane

OTHER

lead

Xinnate AB

INDUSTRY